Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Influence of major BCR-ABL1 transcript subtype on outcome in patients with chronic myeloid leukemia in chronic phase treated frontline with nilotinib.
Genthon A, Nicolini FE, Huguet F, Colin-Gil C, Berger M, Saugues S, Janel A, Hayette S, Cohny-Makhoul P, Cadoux N, Cayuela JM, Campos L, Guyotat D, Flandrin-Gresta P. Genthon A, et al. Among authors: hayette s. Oncotarget. 2020 Jun 30;11(26):2560-2570. doi: 10.18632/oncotarget.27652. eCollection 2020 Jun 30. Oncotarget. 2020. PMID: 32655840 Free PMC article.
Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT).
Michallet AS, Nicolini F, Fürst S, Le QH, Dubois V, Hayette S, Bourgeot JP, Tremisi JP, Thomas X, Gebuhrer L, Michallet M. Michallet AS, et al. Among authors: hayette s. Bone Marrow Transplant. 2005 Mar;35(6):601-8. doi: 10.1038/sj.bmt.1704807. Bone Marrow Transplant. 2005. PMID: 15756285
Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP).
Nicolini FE, Corm S, Lê QH, Sorel N, Hayette S, Bories D, Leguay T, Roy L, Giraudier S, Tulliez M, Facon T, Mahon FX, Cayuela JM, Rousselot P, Michallet M, Preudhomme C, Guilhot F, Roche-Lestienne C. Nicolini FE, et al. Among authors: hayette s. Leukemia. 2006 Jun;20(6):1061-6. doi: 10.1038/sj.leu.2404236. Leukemia. 2006. PMID: 16642048
BCR-ABL mutant kinetics in CML patients treated with dasatinib.
Nicolini FE, Chabane K, Tigaud I, Michallet M, Magaud JP, Hayette S. Nicolini FE, et al. Among authors: hayette s. Leuk Res. 2007 Jun;31(6):865-8. doi: 10.1016/j.leukres.2006.12.003. Epub 2007 Jan 8. Leuk Res. 2007. PMID: 17208297 Clinical Trial.
Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation.
Nicolini FE, Hayette S, Corm S, Bachy E, Bories D, Tulliez M, Guilhot F, Legros L, Maloisel F, Kiladjian JJ, Mahon FX, Lê QH, Michallet M, Roche-Lestienne C, Preudhomme C. Nicolini FE, et al. Among authors: hayette s. Haematologica. 2007 Sep;92(9):1238-41. doi: 10.3324/haematol.11369. Haematologica. 2007. PMID: 17768119 Free article.
118 results